1.
Bakaric A, Cironi L, Praz V, et al. CIC-DUX4 Chromatin Profiling Reveals New Epigenetic Dependencies and Actionable Therapeutic Targets in CIC-Rearranged Sarcomas. Cancers. 2024;16(2). doi:10.3390/cancers16020457.
1.
Bevill SM, Casaní-Galdón S, Farran CAE, et al. Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma. Cell genomics. 2023;3(7):100321. doi:10.1016/j.xgen.2023.100321.
1.
Nakayama RT, Pulice JL, Valencia AM, et al. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet. 2017;49(11):1613-1623. doi:10.1038/ng.3958.
1.
McBride MJ, Kadoch C. Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities. J Pathol. 2018;244(5):638-649. doi:10.1002/path.5042.
1.
Kumar MS, Pester RE, Chen CY, et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 2009;23(23):2700-4. doi:10.1101/gad.1848209.